A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Massachusetts General Hospital
Sponsor:
Collaborators:
FORUM Pharmaceuticals Inc
Information provided by (Responsible Party):
A. Eden Evins, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01480232
First received: November 23, 2011
Last updated: October 1, 2014
Last verified: October 2014

November 23, 2011
October 1, 2014
December 2011
January 2016   (final data collection date for primary outcome measure)
  • Effects of EVP-6124 on 7-day point-prevalence smoking abstinence [ Time Frame: Weeks 1-12 ] [ Designated as safety issue: No ]
    Smoking abstinence is defined as a self-report of smoking no cigarettes for the past 7 days by time-line follow-back, confirmed by expired carbon monoxide (CO) <10 ppm and/or urine cotinine <50 ng/mL.
  • Difference in expired CO concentration [ Time Frame: Weeks 1-12 ] [ Designated as safety issue: No ]
    CO concentration over time will be plotted to determine whether there is variation in the effect of EVP-6124, using a random effect model.
Same as current
Complete list of historical versions of study NCT01480232 on ClinicalTrials.gov Archive Site
  • Effects of EVP-6124 on cognitive performance [ Time Frame: Weeks 1-12 ] [ Designated as safety issue: No ]
    Cognitive performance will be measured using the N-Back Task, Stroop Task, Cambridge Neuropsychological Test Automated Battery, Smoking Emotional Stroop Task, and the Continuous Performance Test - Conners Version. Additional testing will include nicotine craving and withdrawal assessments (Tiffany Questionnaire of Smoking Urges and Wisconsin Smoking Withdrawal Scale) and psychological efficacy assessments (Positive and Negative Affect Scale, Center for Epidemiologic Studies-Depression [CES-D] Scale, and the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire).
  • Safety and tolerability of EVP-6124 alone or combined with NRT [ Time Frame: Weeks 1-14 ] [ Designated as safety issue: Yes ]
    All AEs (adverse experiences) spontaneously reported by subjects and/or observed by investigator and evaluation of physical examinations, prior and concomitant medications, clinical laboratory tests, ECGs, and vital signs measurements.
Same as current
Not Provided
Not Provided
 
A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence
Proof-of-Concept Study of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, Versus Placebo in Subjects With Nicotine Dependence

This study is designed to evaluate the initial evidence for efficacy of the investigational medicine, EVP-6124, to improve smoking cessation outcomes with and without a standard taper of nicotine replacement therapy (NRT) in healthy nicotine dependent smokers

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Nicotine Dependence
  • Smoking Cessation
  • Drug: EVP-6124
    One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
  • Drug: Placebo Capsule
    One placebo capsule ingested orally daily for 12 weeks (84 days)
  • Drug: NicoDerm CQ Patch (Active)
    One NicoDerm CQ patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
  • Drug: NRT Patch (Placebo)
    One NRT patch (Placebo) daily for first 6 weeks (42 days).
  • Behavioral: Brief Supportive and Behavioral Treatment
    Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.
  • Experimental: EVP-6124 + NicoDerm CQ (Active)
    One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm CQ patch (Active) daily for first 6 weeks (42 days)
    Interventions:
    • Drug: EVP-6124
    • Drug: NicoDerm CQ Patch (Active)
    • Behavioral: Brief Supportive and Behavioral Treatment
  • Active Comparator: Placebo + NicoDerm CQ (Active)
    One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm CQ patch (Active) daily for first 6 weeks (42 days)
    Interventions:
    • Drug: Placebo Capsule
    • Drug: NicoDerm CQ Patch (Active)
    • Behavioral: Brief Supportive and Behavioral Treatment
  • Experimental: EVP-6124 + NRT Patch (Placebo)
    One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
    Interventions:
    • Drug: EVP-6124
    • Drug: NRT Patch (Placebo)
    • Behavioral: Brief Supportive and Behavioral Treatment
  • Placebo Comparator: Placebo + NRT Patch (Placebo)
    One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
    Interventions:
    • Drug: Placebo Capsule
    • Drug: NRT Patch (Placebo)
    • Behavioral: Brief Supportive and Behavioral Treatment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
450
January 2016
January 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Self-report of smoking an average of ≥10 cigarettes/day for 6 months and expired CO ≥10 parts per million (ppm) or urine cotinine ≥ 100 ng/mL at screening or self-report of smoking an average of 5-9 cigarettes/day for 6 months and a urine cotinine ≥30ng/ml at screening
  • Have a negative urine drug screen at screening
  • Fertile, sexually active subjects (males and females) must use an effective method of contraception from the first dose of study drug and for 3 months after the last dose of study drug
  • If female and capable of conception, must have a negative urine hCG pregnancy test at screening and Day 1

Exclusion Criteria:

  • Have unstable medical illness with hospitalization for treatment likely within 6 months
  • Have life-threatening arrhythmia, cerebrovascular or cardiovascular event within 6 months of enrollment
  • Have liver function tests elevated >2.5 times the upper limit of normal range
  • Have a tumor or a seizure disorder
  • Currently using other tobacco- or nicotine-containing products and unwilling to try to quit
  • Have a 6-month history of substance use disorder other than nicotine or caffeine or major depressive disorder
  • Have a history of multiple adverse drug reactions
  • Non-response (past 3 months) to NRT >20 mg/day, bupropion >150 mg/day, or varenicline 2 mg/day for ≥4 weeks
  • Use of excluded concomitant medications
  • Hospitalization for any reason within 30 days of screening
  • Use of any investigational drug or device within 30 days of screening
  • Have clinically significant abnormal serum electrolytes
  • Have insufficiently controlled diabetes mellitus
  • Have renal insufficiency (serum creatinine >1.8 mg/dL)
  • Malignant tumor within the last 5 years, with the exception of squamous and basal cell carcinoma or cervical carcinoma in situ
  • Have a clinically significant cardiovascular abnormality on the screening EKG
  • Lifetime history of schizophrenia, bipolar disorder, post-traumatic stress disorder, bulimia, organic mental disorder, dementia, pervasive developmental disorder
  • Have untreated, clinically significant hypothyroidism or hyperthyroidism
  • Have a positive self-report of human immunodeficiency virus infection
  • Females who are pregnant or nursing
  • Any experimental drug currently or within 30 days before baseline
  • Have a serious risk of suicide
  • Have a screening ECG with a corrected QT (QTc) interval using Bazett's formula >450 msec for males and >470 msec for females or the presence of any clinically significant cardiac abnormalities
Both
18 Years to 65 Years
No
Contact: Ailish Hanly, BS 617-724-8472 a7smoking@partners.org
United States
 
NCT01480232
EVP-6124-014, 1R01DA030992-01
Yes
A. Eden Evins, Massachusetts General Hospital
A. Eden Evins
  • FORUM Pharmaceuticals Inc
  • National Institute on Drug Abuse (NIDA)
Principal Investigator: Anne Eden Evins, MD, MPH Massachusetts General Hospital
Principal Investigator: Maurizio Fava, MD Massachusetts General Hospital
Massachusetts General Hospital
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP